A detailed history of M&T Bank Corp transactions in Nuvalent, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 7,281 shares of NUVL stock, worth $613,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,281
Previous 7,281 -0.0%
Holding current value
$613,205
Previous $744,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$67.44 - $112.17 $85,176 - $141,670
1,263 Added 20.99%
7,281 $744,000
Q2 2024

Jul 31, 2024

BUY
$62.76 - $81.61 $41,547 - $54,025
662 Added 12.36%
6,018 $456,000
Q1 2024

May 07, 2024

SELL
$72.35 - $88.99 $238,320 - $293,133
-3,294 Reduced 38.08%
5,356 $402,000
Q4 2023

Feb 06, 2024

SELL
$42.42 - $80.28 $147,536 - $279,213
-3,478 Reduced 28.68%
8,650 $636,000
Q3 2023

Nov 02, 2023

SELL
$39.12 - $49.85 $342,847 - $436,885
-8,764 Reduced 41.95%
12,128 $557,000
Q1 2023

May 11, 2023

BUY
$25.42 - $33.52 $123,337 - $162,639
4,852 Added 30.25%
20,892 $545,000
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $145,926 - $287,504
7,905 Added 97.17%
16,040 $477,000
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $150,172 - $295,869
8,135 New
8,135 $242,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.62B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.